Search peptides, terms, sources/
Metabolic and incretin

Retatrutide

Also known as: LY3437943 · marketed under no brand name as of August 2026

Investigational triple GIP, GLP-1 and glucagon receptor agonist studied for weight management. Not licensed in the UK; studied in a Phase 2 trial.

UK status checked . Evidence last reviewed . By the PeptGuru editorial team (Astute Management).

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Moderate evidence (level 3 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

1 finding at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Retatrutide is recorded as not licensed in the UK (checked 14 November 2026).

Best study type
Human trials2 human trials · 1 lab (in-vitro)

What is Retatrutide?

Retatrutide is an investigational synthetic peptide that acts on the GIP, GLP-1 and glucagon receptors, studied for weight management and liver fat. It is not licensed in the UK. It has been studied in a Phase 2 randomised placebo-controlled trial, with Phase 3 trials registered.

The liver-fat results come from a smaller sub-study.

Class
Incretin mimetic, Triple GIP/GLP-1/glucagon receptor agonist
Origin
Analogue / modified
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does Retatrutide work?

Retatrutide activates three receptors: GIP, GLP-1 and glucagon. The first two affect insulin, stomach emptying and appetite. The glucagon part is proposed to raise energy use and change how the liver handles fat. This explanation comes mainly from a trial paper, so it is still a proposal.

The mechanism in more detail

Retatrutide activates the GIP, GLP-1, and glucagon receptors simultaneously, described in the peer-reviewed literature as the first triple-receptor agonist studied at this stage of clinical development. Its GIP and GLP-1 receptor activity is reported to contribute mechanisms shared with dual agonists in the same drug class, including glucose-dependent insulin secretion, delayed gastric emptying, and reduced appetite.

The added glucagon receptor agonism is proposed in the literature as the mechanistic basis for additional effects on energy expenditure and hepatic fat metabolism, distinguishing retatrutide from dual GIP/GLP-1 agonists and from single GLP-1 agonists. This mechanistic account is drawn from the discussion section of retatrutide’s primary Phase 2 publication rather than a dedicated receptor-pharmacology study, and should be read as a proposed mechanism rather than an independently confirmed one.

Mechanisms and targets

Classification and structure

Names
Retatrutide; LY3437943 (research/development code); marketed under no brand name as of August 2026 (unlicensed)
Class
Incretin mimetic Triple GIP/GLP-1/glucagon receptor agonist
Origin
Analogue / modified
Structure
A synthetic peptide that acts at the glucagon, GIP and GLP-1 receptors (Coskun et al., Cell Metabolism 2022). Exact sequence and modification detail is not given here.
Routes used in the research
Subcutaneous injection in the Phase 2 obesity trial and the Phase 2a liver-fat sub-study.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Retatrutide has 3 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

3 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
11100

Phase 2 obesity trial Moderate

In a phase 2, randomised, placebo-controlled, dose-ranging trial in adults with obesity, the highest dose of retatrutide tested resulted in a mean weight reduction of 24.2% at 48 weeks.

Study type
Human trial
Population
Adults with obesity (BMI 30 or above, or 27 or above with 1 or more weight-related comorbidity), without diabetes; phase 2, multi-dose, double-blind, placebo-controlled.
Source
1 Jastreboff et al., 2023

Limitation: Sponsor-funded (Eli Lilly); Phase 2 dose-ranging design, not yet confirmed at Phase 3 scale in the peer-reviewed literature.

Limitations in full

Sponsor-funded (Eli Lilly); Phase 2 dose-ranging design, not yet confirmed at Phase 3 scale in the peer-reviewed literature. The larger and more widely cited TRIUMPH-1 Phase 3 result cannot be entered as corroboration per this site's source policy until it is peer-reviewed published.

Liver fat in MASLD Limited

In a randomised Phase 2a sub-study in participants with elevated liver fat (metabolic dysfunction-associated steatotic liver disease, MASLD), the two highest doses of retatrutide reduced liver fat by 81.4% and 82.4% at 24 weeks, and 79% and 86% of participants in those groups reached normal liver fat levels (under 5%).

Study type
Human trial
Population
98 participants from the Phase 2 obesity trial with elevated baseline liver fat, randomised sub-study.
Source
2 Sanyal et al., 2024

Limitation: Small sub-study sample (n=98) drawn from within the same Phase 2 programme as the obesity trial above, not a fully separate trial; sponsor-funded.

Triple receptor agonism mechanism Preliminary

Retatrutide activates the GLP-1, GIP, and glucagon receptors simultaneously; glucagon receptor activation is proposed as the mechanistic basis for retatrutide's additional effects on energy expenditure and hepatic fat metabolism beyond what dual GIP/GLP-1 agonists achieve.

Study type
Lab (in-vitro)
Population
Receptor-pharmacology and mechanistic review literature.
Source
1 Jastreboff et al., 2023

Limitation: No dedicated receptor-pharmacology paper is cited for retatrutide.

What safety findings have been reported?

3 safety findings are recorded for Retatrutide. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Gastrointestinal adverse events

In the Phase 2 obesity trial, gastrointestinal adverse events (nausea, diarrhoea, vomiting, constipation) occurred more frequently with retatrutide than placebo and were dose-related. Events were reported as mostly mild to moderate.

Source
1 Jastreboff et al., 2023

Heart rate increase

Heart rate increased in a dose-dependent manner with retatrutide in the Phase 2 trial, peaking around week 24 and declining thereafter.

Source
1 Jastreboff et al., 2023

Serious events and discontinuations

The incidence of serious adverse events in the Phase 2 trial was reported as 4% in the placebo group and ranging from 0% to 6% across retatrutide dose groups. Adverse events leading to discontinuation occurred in 6 to 16% of retatrutide recipients versus none of the placebo recipients.

Source
1 Jastreboff et al., 2023

What is Retatrutide's UK regulatory status?

Marketing authorisation
Not licensed. No MHRA marketing authorisation exists for retatrutide as of August 2026.
Prescription status
Not applicable; there is no licensed UK product to classify. Retatrutide has no lawful UK prescribing pathway outside a registered clinical trial.
Medicine class
Unlicensed/investigational medicinal product, not a licensed medicine in the UK.
MHRA position
No MHRA-authorised product exists. Retatrutide is in Phase 3 clinical development (TRIUMPH programme, registered on ClinicalTrials.gov, for example TRIUMPH-1, NCT05929066).
Authorised use
None.
Research use
Retatrutide has been studied under formal clinical-trial frameworks (Phase 2 and Phase 3) by its developer. The MHRA says retatrutide is not authorised in the UK and that products sold as retatrutide outside clinical trials are supplied illegally. It reports seizing unlicensed retatrutide pens in 2025 and 2026 (MHRA press releases of 24 October 2025, 29 May 2026 and 15 October 2026).
Other restrictions
As an unlicensed medicinal product, retatrutide falls under the general UK framework for unlicensed medicines (Human Medicines Regulations 2012), a general statutory framework applied by inference to retatrutide's category, not a retatrutide-specific regulatory document naming the compound.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Retatrutide is recorded as not licensed in the UK (checked 14 November 2026).

References

3 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of MedicineHuman clinical trial, RCT · DOI 10.1056/NEJMoa2301972 · Original ↗
  2. Sanyal AJ, Kaplan LM, Frias JP, et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature MedicineHuman clinical trial, RCT · DOI 10.1038/s41591-024-03018-2 · Original ↗
  3. MHRA (2026). Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police. GOV.UK press release, 15 October 2026 · Original ↗

Questions about Retatrutide

What is Retatrutide?

Retatrutide is an investigational synthetic peptide that acts on the GIP, GLP-1 and glucagon receptors, studied for weight management and liver fat. It is not licensed in the UK. It has been studied in a Phase 2 randomised placebo-controlled trial, with Phase 3 trials registered. Read what it is.

Is Retatrutide licensed in the UK?

PeptGuru records Retatrutide's UK status as: Not licensed in the UK. Not licensed. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Retatrutide show?

PeptGuru records 3 research findings for Retatrutide: 2 from human trials and 1 from a lab (in-vitro) study. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Retatrutide?

3 safety findings are recorded, including: gastrointestinal adverse events; heart rate increase; serious events and discontinuations. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Retatrutide?

All 3 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • Correction · Liver-fat figures corrected to the published 24-week values. Unsourced heart-rate and nausea figures removed. UK position now cites MHRA statements.

How findings are graded: the grading method. All changes.

  • Liraglutide

    Earlier-generation GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; licence status depends on the brand.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateLicensed UK medicine
  • Semaglutide

    GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • Tirzepatide

    Dual GIP and GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • Mazdutide

    Not authorised in the UK; approved in China. Peptide that activates glucagon and GLP-1 receptors, studied in phase 3 trials in Chinese adults.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongNot licensed in the UK

Compare Retatrutide with Liraglutide

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.